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Abstract
Background
We previously reported increased unstimulated blood levels of interferon-gamma in persons
with latent tuberculosis infection (LTBI) in the United States, suggesting enhanced immune
activation in LTBI. To investigate this further in a TB-endemic setting, we assessed inter-
feron-gamma levels in persons with and without LTBI in Peru.
Methods
We analyzed data from patients with and without a recent type 1 (spontaneous) acute myo-
cardial infarction (AMI) who were enrolled from two public hospital networks in Lima, Peru,
and underwent LTBI testing using the QuantiFERON® TB Gold In-tube (QFT) assay. Partic-
ipants with a positive QFT test were defined as having LTBI, whereas participants with a
negative QFT test were defined as non-LTBI. Unstimulated interferon-gamma was quanti-
fied via enzyme-linked immunosorbent assay in the QFT nil-tube, which does not contain
antigens. We compared unstimulated interferon-gamma levels between LTBI and non-LTBI
groups using the Wilcoxon rank sum test. We used proportional odds modeling for multivari-
able analysis.
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Results
Data from 214 participants were included in this analysis. Of those, 120 (56%) had LTBI.
There were no significant differences in age, sex and comorbidities between LTBI and non-
LTBI participants, except for recent AMI that was more frequent in LTBI. LTBI participants
had higher unstimulated interferon-gamma levels compared to non-LTBI participants
(median, interquartile range; 14 pg/mL, 6.5–52.8 vs. 6.5 pg/mL, 4.5–15; P<0.01). LTBI
remained associated with higher unstimulated interferon-gamma levels after controlling for
age, sex, recent AMI, history of hypertension, diabetes mellitus, dyslipidemia, end stage
renal disease, malignancy, obesity, and tobacco use (adjusted odds ratio, 2.93; 95% confi-
dence interval, 1.8–4.9). In a sensitivity analysis that excluded participants with AMI, the
association between unstimulated interferon-gamma and LTBI remained present (adjusted
odds ratio; 3.93; 95% confidence interval, 1.9–8.2).
Conclusions
LTBI was associated with higher unstimulated interferon-gamma levels. These data suggest
ongoing immune activation in LTBI.
Introduction
Latent tuberculosis infection (LTBI) affects approximately one fourth of the world population
[1]. It is estimated that 5 to 10% of persons with LTBI will progress to active TB disease during
their lifetime [2–4]. The other 90 to 95% will remain “latently” infected. Individuals considered
at high risk for TB disease progression should receive LTBI therapy based on current screening
and treatment guidelines [5, 6].
The classic model of LTBI proposed that mycobacteria contained within infected granulo-
mas remain dormant. Recent research shows that LTBI is not a completely quiescent state,
with wide heterogeneity in mycobacterial metabolic activity and host immune responses
within each granuloma [7, 8]. Animal models provide evidence that subsets of mycobacteria
undergo replication in chronic Mycobacterium tuberculosis infection [9]. Clinically, the activity
of mycobacteria in LTBI is suggested by the effectiveness of isoniazid in preventing progres-
sion to TB disease, as isoniazid acts on mycolic acid cell wall synthesis and is primarily effective
against dividing organisms [10–12]. LTBI has been associated with increased expression of
pro-inflammatory mediators, suggesting persistent immune activation related to unresolved
infection [13, 14].
Using data from the U.S. National Health Nutritional Examination Survey (NHANES), we
previously reported an association between LTBI and elevated unstimulated blood levels of
interferon-gamma (IFN-γ), a central cytokine in monocyte/macrophage activation usually
produced by activated T cells and natural killer cells [15]. To further assess this finding, we per-
formed a secondary analysis of IFN-γ levels in participants of a cardiovascular disease study
conducted in Peru, who underwent LTBI testing via the QuantiFERON1 TB Gold-In tube
(QFT) assay [16]. By studying this population, we sought to examine IFN-γ levels in a setting
where M. tuberculosis infection is endemic and therefore chances of re-exposure to the patho-
gen and interactions with the host immune system may be more noticeable; widespread use of
Bacillus Calmette-Guerin (BCG) vaccine in this population also distinguishes it from the U.S.
population.
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Materials and methods
The primary study was approved by the institutional review boards of the University of Ken-
tucky and the University of Cincinnati in the US, and the ethical committees of Hospital
Nacional Dos de Mayo and Hospital Nacional Edgardo Rebagliati Martins in Peru. All partici-
pants provided informed written consent for collection of study data. Participants were origi-
nally enrolled in a case-control study of patients with and without a recent type 1
(spontaneous) acute myocardial infarction (AMI) conducted in Hospital Nacional Dos de
Mayo and Hospital Nacional Edgardo Rebagliati Martins in Lima, Peru between July of 2015
and March of 2017. Cases were patients who had been diagnosed with their first type 1 AMI
within one year of study entry. Controls were patients recruited from these same hospital net-
works who did not have a history of AMI, stroke or peripheral vascular disease. Cases and con-
trols were required not to have clinical evidence of active TB disease at time of study entry.
Persons with history of human immunodeficiency virus (HIV) infection, TB disease, and/or
LTBI treatment were excluded. A detailed description of the recruiting parameters were previ-
ously published [16]. Participants’ demographic information and medical history were col-
lected by self-report. Medical charts were reviewed to confirm accuracy of medical history
data provided by participants. QFT testing was performed in all participants by a trained
research laboratory technician as instructed by the manufacturer [17]. Briefly, the procedures
followed for QFT testing were: 1) 1 mL of blood was collected into each of 3 QFT tubes: a nil
tube (negative control tube without antigens), a TB antigen tube (containing the Mycobacte-
rium tuberculosis antigens ESAT-6, CFP-10 and TB7.7), and a mitogen tube (positive control
tube containing the T cell mitogen phytohemagglutinin); 2) after mixing, the tubes were incu-
bated upright at 37˚C as soon as possible and within 16 hours of collection. Following a 16- to
24-hour incubation period, the tubes were centrifuged and plasma was stored frozen until fur-
ther analysis; 3) the concentration of IFN-γ in each plasma specimen was determined using
enzyme-linked immunosorbent assay (ELISA). For interpretation of results, the TB response
is calculated as the difference in plasma IFN-γ concentration from the TB antigen tube minus
the nil tube. TB responses 0.35 IU/mL (17.5 pg/mL) and 25% of nil tube value were con-
sidered positive, while TB responses < 0.35 IU/mL (17.5 pg/mL) or TB responses 0.35 IU/
mL (17.5 pg/mL) but< 25% of nil value were considered negative. Indeterminate results were
defined as IFN-γ concentrations < 0.50 lU/mL (25 pg/mL) in the mitogen tube minus nil tube,
or an IFN-γ value > 8.0 lU/mL (400 pg/mL) in the nil tube [18]. Participants with indetermi-
nate QFT results were excluded from this study. Primary results of the QFT test based on the
response to TB antigens were presented previously [16].
We then extracted the IFN-γ values obtained in the QFT nil tubes to examine IFN-γ levels
without any in vitro antigenic stimulation. Because a non-normal distribution of IFN-γ values
was expected based on previous studies, we summarized IFN-γ levels as median and interquar-
tile ranges (IQR) and compared these levels between LTBI and non-LTBI groups using the
Wilcoxon rank sum test. For multivariable analysis, we used proportional odds modeling to
estimate the association between IFN-γ levels and LTBI, after adjusting for potential con-
founders. This model assumes the odds of having an IFN-γ value in any quartile higher than
the Nth or lower is independent of N = 1, 2, and 3 [19]. We used Stata software (version 12.0)
for statistical analyses. P values < 0.05 were considered statistically significant. All P values
were 2-tailed. All participants provided informed written consent for collection of study data.
Results
Data from 214 participants were included in this analysis. Median age was 62 years (IQR, 56–
70), 69% were male, 65% had hypertension, 40% had dyslipidemia, 39% had diabetes mellitus,
Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma
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30% reported tobacco use, and 23% were obese (body mass index30 kg/m2). There were 120
(56%) persons with LTBI and 94 (44%) persons without LTBI based on QFT results. Partici-
pant characteristics were not significantly different between the LTBI and non-LTBI groups
except for recent AMI (Table 1), which was more frequent in the LTBI group as previously
reported [16].
The median values of unstimulated IFN-γ in the QFT nil tube stratified by participant char-
acteristics are shown in Table 2. Unstimulated IFN-γ concentrations were significantly higher
in persons with LTBI compared to persons without LTBI (median, IQR; 14 pg/mL, 6.5–52.8
vs. 6.5 pg/mL, 4.5–15; P<0.01). The log-transformed IFN-γ levels in the QFT nil tube of per-
sons with and without LTBI are shown in Fig 1. In multivariable analysis, the proportional
odds of being in a higher quartile of IFN-γ distribution was almost 3-fold higher for persons
with LTBI compared to persons without LTBI, after controlling for age, sex, history of hyper-
tension, diabetes mellitus, dyslipidemia, end stage renal disease, malignancy, tobacco use, obe-
sity and recent AMI (adjusted odds ratio; 2.93, 95% confidence interval, 1.8–4.9). Complete
results of the final proportional odds model are shown in Table 3. The proportional odds
assumption was not violated (likelihood-ratio test of proportionality of odds, P = 0.47; Brant
Table 1. Characteristics of participants with and without latent tuberculosis infection (LTBI).
Characteristic LTBI
(n = 120)
No LTBI
(n = 94)
P value
Age in years, median (IQR) 63 (57–68) 61 (55–72) 0.26
Male sex 86 (72%) 62 (66%) 0.37
History of hypertension 76 (63%) 62 (66%) 0.69
History of diabetes mellitus 45 (38%) 38 (40%) 0.66
History of dyslipidemia 49 (41%) 36 (38%) 0.71
End stage renal disease 4 (3%) 2 (2%) 0.60
History of malignancy 6 (5%) 5 (5%) 0.93
Tobacco use 41 (34%) 24 (26%) 0.17
Obesity 25 (21%) 25 (27%) 0.38
Recent acute myocardial infarction 67 (56%) 38 (40%) 0.03
https://doi.org/10.1371/journal.pone.0202191.t001
Table 2. Interferon-gamma levels in the unstimulated QuantiFERON1 nil tube stratified by participant
characteristics.
Characteristic Presence of characteristic P value
Yes a No a
Age above 60 years old 9.5 (5–32.5) 10.5 (6–39.5) 0.76
Male sex 10 (5–35) 9.8 (5.5–32) 0.83
History of hypertension 10 (6–32.5) 9.8 (4.8–46.3) 0.68
History of diabetes mellitus 8.5 (5.5–31.5) 11 (5–41.5) 0.85
History of dyslipidemia 9.5 (5.5–44) 10 (5.5–29.5) 0.59
End stage renal disease 19.8 (6.5–45.5) 10 (5.5–34.5) 0.53
History of malignancy 8.5 (4.5–67) 10 (5.5–34.5) 0.99
Tobacco use 12 (5–86.5) 8.5 (5.5–29) 0.08
Obesity 11.3 (6–36) 9 (5.5–32.5) 0.35
Recent myocardial infarction 11.5 (5.5–41.5) 8.5 (5.5–31.5) 0.16
Latent tuberculosis infection 14 (6.5–52.8) 6.5 (4.5–15) <0.01
a Interferon-gamma values in pg/mL presented as median and interquartile range in parenthesis
https://doi.org/10.1371/journal.pone.0202191.t002
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Fig 1. Log of interferon-gamma levels in the unstimulated QuantiFERON1 nil tube in persons with and without latent tuberculosis infection (LTBI).
https://doi.org/10.1371/journal.pone.0202191.g001
Table 3. Results of the final proportional odds model for being in a higher quartile of interferon-gamma
distribution.
Variable Adjusted odds ratio (95% CI)
Latent tuberculosis infection 2.93 (1.76–4.9)
Age, per year increase 0.99 (0.96–1.01)
Male sex 0.80 (0.45–1.43)
History of hypertension 1.03 (0.59–1.8)
History of diabetes mellitus 0.95 (0.55–1.64)
History of dyslipidemia 1.09 (0.59–1.8)
End stage renal disease 1.74 (0.63–1.86)
History of malignancy 0.83 (0.24–2.86)
Tobacco use 1.46 (0.8–2.65)
Obesity 1.36 (0.74–2.49)
Recent acute myocardial infarction 1.16 (0.69–1.98)
https://doi.org/10.1371/journal.pone.0202191.t003
Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma
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test of parallel regression assumption, P = 0.37). In a sensitivity analysis that excluded partici-
pants with recent AMI, the association between IFN-γ and LTBI remained present (adjusted
odds ratio; 3.93; 95% confidence interval, 1.9–8.2). In a model that only included data from
participants with LTBI, we found that none of the participants’ characteristics influenced
unstimulated IFN-γ levels within the LTBI population. S1 File contains a de-identified study
dataset.
Because diabetes mellitus induces a dysfunctional immunologic state and is increasingly
recognized as a risk factor for developing LTBI and TB disease [20, 21], we conducted a sub-
analysis of unstimulated IFN-γ concentrations restricted to the study population with this con-
dition (n = 83). Similar to the results in the overall population, we found that unstimulated
IFN-γ levels were higher in diabetic individuals with LTBI compared to no LTBI (median,
IQR; 13.5 pg/mL, 6.5–50 vs. 6.8 pg/mL, 4–14; P<0.01).
To explore if unstimulated IFN-γ levels in the nil tube influence M. tuberculosis-specific
responses, we assessed the correlation between IFN-γ values in the nil and TB antigen tubes.
We found a modest correlation in all subjects (Spearman rho = 0.59; P<0.001) and among
LTBI individuals (Spearman rho = 0.56; P<0.01). We also assessed the correlation between
IFN-γ levels in the nil and mitogen tubes. This analysis was limited by a large number of par-
ticipants with IFN-γ values reported as>10 IU/mL in the mitogen tube (58% of all individu-
als), who were assigned an absolute value of 10 IU/mL for purposes of this analysis. We found
a weak correlation between IFN-γ levels in the nil and mitogen tubes (Spearman rho = 0.22;
P = 0.01).
Discussion
We showed that unstimulated blood levels of IFN-γ are higher in persons with LTBI compared
to persons without LTBI in a TB-endemic setting such as Lima, Peru. The association between
higher IFN-γ levels and LTBI remained present after adjusting for multiple potential con-
founders. These results are consistent with our previous report of elevated IFN-γ levels in a U.
S. population with LTBI [15]. Our results are also consistent with a recent study conducted in
Seattle, Washington that found higher geometric mean of QFT nil-tube IFN-γ values in QFT
positive vs. QFT negative individuals with and without HIV infection, although these differ-
ences were not adjusted by comorbidities [22].
IFN-γ is an important pro-inflammatory cytokine involved in innate and adaptive
responses to infection. IFN-γ may be produced by activated lymphocytes, natural killer cells
and type 1 innate lymphoid cells [23]. Although the source of IFN-γ in QFT nil tubes is
unknown, it may indicate spontaneous IFN-γ secretion by activated lymphocytes and/or other
blood cells, thus reflecting a degree of ongoing immune activation in LTBI patients. Support-
ing this idea, IFN-γ levels in QFT nil tubes are elevated in individuals with other conditions
characterized by chronic immune activation such as HIV infection, even when HIV viral loads
are< 200 copies/mL [22].
The potential unfavorable consequences of enhanced chronic immune activation in LTBI
have been poorly defined. We recently reported an association between LTBI and AMI in this
same study population of middle-aged and elderly patients with multiple comorbidities; how-
ever, future studies are needed to confirm this finding in other settings [16]. Whether LTBI
treatment decreases immune activation requires further investigation, as it could challenge the
current paradigm of LTBI management by expanding screening to individuals at increased
risk of cardiovascular events and other inflammatory-mediated complications.
Our analysis had limitations. Prior studies showed that unstimulated IFN-γ levels were
associated with total peripheral blood lymphocyte counts [15, 22]. We did not measure
Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma
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lymphocyte counts and therefore could not account for this potential confounder. However,
since ours consisted of an HIV-negative population and baseline characteristics were similar
between the LTBI and non-LTBI groups, unbalanced differences in lymphocyte counts con-
founding our primary findings are unlikely. Most participants with AMI were recruited within
30 days of their AMI event and therefore IFN-γ concentrations could have been affected by
their recent AMI occurrence and/or treatment. To account for this potential confounder, our
multivariable analysis adjusted for AMI events and showed an independent association
between higher IFN-γ levels and LTBI. Furthermore, in a sensitivity analysis that excluded par-
ticipants with AMI, the association between IFN-γ and LTBI remained present. Unstimulated
IFN-γ levels seemed overall higher than levels reported in prior studies [15, 22], likely because
our population was older, primarily inpatient, comorbidities were frequent, and socioeco-
nomic conditions were different across studies. Therefore, these results should not be general-
ized to the overall population. Nevertheless, our study sample is representative of individuals
who may benefit the most from interventions to decrease immune activation. Although having
a positive QFT was associated with higher unstimulated IFN-γ responses in our study popula-
tion, we were unable to investigate whether higher unstimulated IFN-γ levels are associated
with an increased (or decreased) risk of progression to TB disease, or whether IFN-γ could be
used as a biomarker to target preventive therapy. Prospective studies of baseline unstimulated
IFN-γ among persons with and without LTBI, and subsequent TB risk could answer these
questions.
In conclusion, our data adds to the growing literature that indicates ongoing immune acti-
vation in persons with LTBI. Since LTBI has a wide phenotypic spectrum, studies are needed
to identify factors and define LTBI subsets associated with higher immune activation profiles.
Similarly, the potential effect of LTBI therapy on immune activation parameters requires fur-
ther investigation.
Supporting information
S1 File. Dataset. This file contains a de-identified dataset related to the findings described in
the manuscript.
(XLSX)
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